Mackenzie Financial Corp Has $110,000 Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Mackenzie Financial Corp reduced its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 13.9% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 18,183 shares of the company’s stock after selling 2,936 shares during the period. Mackenzie Financial Corp’s holdings in Amneal Pharmaceuticals were worth $110,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of Amneal Pharmaceuticals by 3.1% during the third quarter. Vanguard Group Inc. now owns 13,548,300 shares of the company’s stock worth $57,174,000 after acquiring an additional 412,599 shares in the last quarter. Rubric Capital Management LP increased its holdings in Amneal Pharmaceuticals by 54.7% during the 3rd quarter. Rubric Capital Management LP now owns 4,024,500 shares of the company’s stock worth $16,983,000 after purchasing an additional 1,423,121 shares in the last quarter. LSV Asset Management raised its stake in shares of Amneal Pharmaceuticals by 10.5% in the 3rd quarter. LSV Asset Management now owns 1,429,300 shares of the company’s stock valued at $6,032,000 after purchasing an additional 136,100 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Amneal Pharmaceuticals by 3.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,302,633 shares of the company’s stock valued at $5,497,000 after purchasing an additional 47,599 shares during the period. Finally, Phocas Financial Corp. bought a new stake in shares of Amneal Pharmaceuticals in the fourth quarter valued at about $4,339,000. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Trading Up 1.2 %

NASDAQ AMRX opened at $5.94 on Tuesday. The company has a current ratio of 1.63, a quick ratio of 0.94 and a debt-to-equity ratio of 121.31. The stock has a 50 day moving average of $5.72 and a 200-day moving average of $5.22. Amneal Pharmaceuticals, Inc. has a 12 month low of $1.74 and a 12 month high of $6.46. The company has a market cap of $1.82 billion, a PE ratio of -19.16 and a beta of 1.33.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its earnings results on Friday, March 1st. The company reported $0.12 EPS for the quarter, topping the consensus estimate of $0.05 by $0.07. Amneal Pharmaceuticals had a positive return on equity of 126.04% and a negative net margin of 3.51%. The company had revenue of $616.98 million during the quarter, compared to the consensus estimate of $630.67 million. On average, equities research analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.5 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on AMRX. Barclays lifted their target price on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a research report on Monday, January 29th. StockNews.com lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, March 4th. Piper Sandler raised their target price on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a research report on Thursday, March 21st. Finally, The Goldman Sachs Group lifted their price target on shares of Amneal Pharmaceuticals from $5.50 to $6.25 and gave the company a “buy” rating in a research note on Monday, March 4th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Amneal Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $7.31.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.